



03<sup>rd</sup> February, 2025

Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G. Block,  
Bandra- Kurla Complex,  
Bandra East, Mumbai-400 051

The Department of Corporate Services-  
Listing  
The BSE Ltd.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

Symbol- DHANUKA

Scrip Code : 507717

**Sub: Integrated Filing (Financials) for the Quarter and Nine-Month ended on December 31, 2024:**

Dear Sir,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financial) for the Quarter and Nine-Months period ended December 31, 2024.

The above information is also available on the website of the Company at [www.dhanuka.com](http://www.dhanuka.com)

Please take the above information in your record.

*for Dhanuka Agritech Limited*

**Jitin Sadana**  
Company Secretary and Compliance Officer  
FCS-7612

**Independent Auditor's Limited Review Report on the Quarterly and Year To Date Unaudited Standalone Financial Results of Dhanuka Agritech Limited Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended**

**To**  
**The Board of Directors of**  
**Dhanuka Agritech Limited**

We have reviewed the accompanying Statement of unaudited standalone financial results of **Dhanuka Agritech Limited** ("the Company") for the quarter ended December 31, 2024 and Year to date from April 01, 2024 to December 31, 2024 ('the "Statement"') attached herewith, being submitted by the Company pursuant to the requirement of regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S S Kothari Mehta & Co. LLP**  
Chartered Accountants  
Firm Registration No. 000756N/N500441



**Jalaj Soni**  
Partner  
Membership No. 528799  
UDIN: 25528799BMIHUB8291

Place: Gurugram  
Date: February 03, 2025

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024						
		Quarter Ended			Nine Months Ended	
					Year Ended	
S.No	Particulars	31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)
					31.03.2024 (Audited)	
I	Revenue from Operations	44,527.21	65,427.84	40,324.42	1,59,312.86	1,39,023.23
II	Other income	701.32	1,080.13	727.89	2,494.93	1,968.03
III	<b>Total Income (I+II)</b>	<b>45,228.53</b>	<b>66,507.97</b>	<b>41,052.31</b>	<b>1,61,807.79</b>	<b>1,40,991.26</b>
IV	<b>Expenses</b>					
a)	Cost of materials consumed	17,071.67	33,588.08	19,989.10	80,013.95	66,895.51
b)	Purchase of Stock In Trade	3,128.38	4,968.51	4,407.99	15,834.26	18,484.11
c)	Changes in inventories of finished goods, work-in progress and Stock In Trade	6,539.52	(728.52)	366.87	970.95	1,073.93
d)	Employee benefit expenses	4,233.80	4,672.04	4,001.49	13,185.69	11,819.38
e)	Finance costs	143.42	105.12	73.58	331.97	238.50
f)	Depreciation and amortisation expense	1,305.98	1,267.20	1,288.00	3,801.07	2,738.73
g)	Other expenses	5,998.09	6,969.67	5,342.70	18,622.07	16,015.20
	<b>Total Expenses</b>	<b>38,420.86</b>	<b>50,842.10</b>	<b>35,469.73</b>	<b>1,32,759.96</b>	<b>1,17,265.36</b>
V	<b>Profit/(Loss) Before Exceptional Items and Tax (III-IV)</b>	<b>6,807.67</b>	<b>15,665.87</b>	<b>5,582.58</b>	<b>29,047.83</b>	<b>23,725.90</b>
VI	Exceptional items	-	-	-	-	-
VII	<b>Profit/(Loss) Before Tax (V-VI)</b>	<b>6,807.67</b>	<b>15,665.87</b>	<b>5,582.58</b>	<b>29,047.83</b>	<b>23,725.90</b>
VIII	<b>Tax expenses</b>					
a)	Current Tax	1,919.00	3,938.35	1,451.69	7,624.01	5,945.19
b)	Tax of earlier year provided / (written back)	(351.57)	-	(379.47)	(351.57)	(379.47)
c)	Deferred Tax	(264.23)	(24.30)	(26.54)	(370.41)	152.47
IX	<b>Profit/(loss) for the period (VII-VIII)</b>	<b>5,504.47</b>	<b>11,751.82</b>	<b>4,536.90</b>	<b>22,145.80</b>	<b>18,007.71</b>
X	<b>Other Comprehensive Income</b>					
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total Other Comprehensive Income /(Loss) for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>105.55</b>
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>5,504.47</b>	<b>11,751.82</b>	<b>4,536.90</b>	<b>22,145.80</b>	<b>18,007.71</b>
XII	Paid-up equity share capital [Face value of ₹ 2 per share]	901.57	901.57	911.57	901.57	911.57
XIII	Other Equity as per audited Balance Sheet					1,24,676.01
XIV	<b>Earning per share* (in ₹)</b>					
a)	Basic EPS	12.25	25.83	9.95	48.81	39.51
b)	Diluted EPS	12.25	25.83	9.95	48.81	39.51

See accompanying notes to the financial results

\*Actuals for the quarter and nine months not annualised

## Notes:

- The above Unaudited Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors in their Meeting held on February 03, 2025. The Statutory Auditors of the Company have conducted a "Limited Review" of the above Financial Results for the quarter and nine months ended December 31, 2024.
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The demand of Company's products depends on monsoon, pest infestation and crop patterns. Hence there may be variations in the Results from one period to another period.
- The Company has only one reportable Business segment viz. "Agro Chemicals"
- During nine months ended December 31, 2024, the Company has bought back its 5,00,000 nos. of fully paid up equity shares, representing 1.10% of the total issued and paid up equity share capital of the Company @ Rs. 2000/- per equity share aggregating to an amount of Rs. 100.00 Crores and extinguished those shares on September 11, 2024. Consequently, Paid up Share Capital has been reduced by Rs.10,00,000.
- During the quarter ended December 31, 2024, the Company has entered into various agreements with Bayer AG, Germany to acquire international rights to the active ingredients Iprovalicarb and Triadimenol. With this acquisition, Dhanuka plans to expand its footprint in more than 20 countries, including the regions of LATAM, EMEA and Asia including India.
- The Results can also be viewed at our website [www.dhanuka.com](http://www.dhanuka.com) and on the website of BSE & NSE where the Company's shares are listed i.e. at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively. Any query from investors can be sent on email at [investors@dhanuka.com](mailto:investors@dhanuka.com).

For and on behalf of  
Dhanuka Agritech Limited




(M.K. Dhanuka)  
Chairman  
DIN : 00628039

Place : Gurugram (Haryana)

Dated : February 03, 2025

Registered Office : 32, Ashwamekha Marg, 1<sup>st</sup> Floor, Jyoti Nagar, Gurugram, Haryana - 122002, India. Tel: +91-124-4345000

**Corporate & Registered Office :** Global Gateway Towers, Near Guru Dronacharya Metro Station, MG Road, Gurugram -122002, Haryana (INDIA)  
Tel.: +91-124-434 5000, E-mail : [headoffice@dhanuka.com](mailto:headoffice@dhanuka.com), Website: [www.dhanuka.com](http://www.dhanuka.com), CIN: L24219HR1985PLC122802

**Independent Auditor's Limited Review Report on the Quarterly and Year To Date Unaudited Consolidated Financial Results of Dhanuka Agritech Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To**  
**The Board of Directors of**  
**Dhanuka Agritech Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Dhanuka Agritech Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended December 31, 2024 and Year to date from April 01, 2024 to December 31, 2024 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, as amended, to the extent applicable.

4. The Statement includes the results of the following entity :-

**Subsidiary:-**

- i. Dhanuka Chemicals Private Limited (Struck-off w.e.f. 16<sup>th</sup> July, 2024). Also Refer paragraph Below.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.



**SS KOTHARI MEHTA**  
**& CO. LLP**  
CHARTERED ACCOUNTANTS


6. As per the information & explanations given to us, the wholly owned subsidiary of the company, Dhanuka Chemicals Private Limited (DCPL) has been Struck-off and has no operations for the quarter ended December 31, 2024. The DCPL made a voluntary application with the jurisdictional Registrar of Companies ("ROC"), to strike off its name from the register of companies. Consequently, the name of DCPL has been struck off from the record of ROC w.e.f. 16<sup>th</sup> July, 2024 and it ceased to be the Wholly Owned Subsidiary of the Company. (Refer note no.05 of the statement). Therefore, the Statement does not include any financial results for this subsidiary for the quarter ended December 31, 2024 & period from April 1, 2024 to December 31, 2024.

Our conclusion on the Statement is not modified in respect of the above matter.

For **S S Kothari Mehta & Co. LLP**

Chartered Accountants

Firm Reg. No. – 000756N/N500441



**Jalaj Soni**

Partner

Membership No. 528799

UDIN: 255287998MIHUC6996

Place: Gurugram


Date: February 03, 2025

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024						
₹ In lacs						
S.No	Particulars	Quarter Ended			Nine Months Ended	
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
I	Revenue from Operations	44,527.21	65,427.84	40,324.42	1,59,312.86	1,39,023.23
II	Other income	701.32	1,080.13	727.89	2,494.93	1,968.03
III	<b>Total Income (I+II)</b>	<b>45,228.53</b>	<b>66,507.97</b>	<b>41,052.31</b>	<b>1,61,807.79</b>	<b>1,40,991.26</b>
IV	<b>Expenses</b>					
a)	Cost of materials consumed	17,071.67	33,588.08	19,989.10	80,013.95	66,895.51
b)	Purchase of Stock In Trade	3,128.38	4,968.51	4,407.99	15,834.26	18,484.11
c)	Changes in inventories of finished goods, work-in progress and Stock In Trade	6,539.52	(728.52)	366.87	970.95	1,073.93
d)	Employee benefit expenses	4,233.80	4,672.04	4,001.49	13,185.69	11,819.38
e)	Finance costs	143.42	105.12	73.58	331.97	238.50
f)	Depreciation and amortisation expense	1,305.98	1,267.20	1,288.00	3,801.07	2,738.73
g)	Other expenses	5,998.09	6,969.67	5,342.70	18,622.07	16,015.20
	<b>Total Expenses</b>	<b>38,420.86</b>	<b>50,842.10</b>	<b>35,469.73</b>	<b>1,32,759.96</b>	<b>1,17,265.36</b>
V	<b>Profit/(Loss) Before Exceptional Items and Tax (III-IV)</b>	<b>6,807.67</b>	<b>15,665.87</b>	<b>5,582.58</b>	<b>29,047.83</b>	<b>23,725.90</b>
VI	Exceptional items	-	-	-	-	-
VII	<b>Profit/(Loss) Before Tax (V-VI)</b>	<b>6,807.67</b>	<b>15,665.87</b>	<b>5,582.58</b>	<b>29,047.83</b>	<b>23,725.90</b>
VIII	<b>Tax expenses</b>					
a)	Current Tax	1,919.00	3,938.35	1,451.69	7,624.01	5,945.19
b)	Tax of earlier year provided / (written back)	(351.57)	-	(379.47)	(351.57)	(379.47)
c)	Deferred Tax	(264.23)	(24.30)	(26.54)	(370.41)	152.47
IX	<b>Profit/(loss) for the period (VII-VIII)</b>	<b>5,504.47</b>	<b>11,751.82</b>	<b>4,536.90</b>	<b>22,145.80</b>	<b>18,007.71</b>
X	<b>Other Comprehensive Income</b>					
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total Other Comprehensive Income/(Loss) for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>5,504.47</b>	<b>11,751.82</b>	<b>4,536.90</b>	<b>22,145.80</b>	<b>18,007.71</b>
XII	Paid-up equity share capital [Face value of ₹ 2 per share]	901.57	901.57	911.57	901.57	911.57
XIII	Other Equity as per audited Balance Sheet					
XIV	<b>Earning per share* (in ₹)</b>					
a)	Basic EPS	12.25	25.83	9.95	48.81	39.51
b)	Diluted EPS	12.25	25.83	9.95	48.81	39.51

See accompanying notes to the financial results  
\*Actuals for the quarter and nine months not annualised

## Notes:

- The above Unaudited Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors in their Meeting held on February 03, 2025. The Statutory Auditors of the Company have conducted a "Limited Review" of the above Financial Results for the quarter and nine months ended December 31, 2024.
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The demand of Groups's products depends on monsoon, pest infestation and crop patterns. Hence there may be variations in the Results from one period to another period.
- The Group has only one reportable Business segment viz. "Agro Chemicals".
- The Board of Directors of Dhanuka Agritech Limited in its meeting held on November 07, 2023 had approved the Strike off of its wholly owned subsidiary i.e. Dhanuka Chemicals Private Limited (DCPL). DCPL has filed an application for strike-off with the Registrar of Companies (ROC), NCT of Delhi and Haryana. The ROC has approved the strike off and the name of the Company has been struck off with effect from July 16, 2024 from the Register of the Companies.
- During nine months ended December 31, 2024, the Company has bought back its 5,00,000 nos. of fully paid up equity shares, representing 1.10% of the total issued and paid up equity share capital of the Company @ Rs. 2000/- per equity share aggregating to an amount of Rs. 100.00 Crores and extinguished those shares on September 11, 2024. Consequently, Paid up Share Capital has been reduced by Rs.10,00,000.
- During the quarter ended December 31, 2024, the Company has entered into various agreements with Bayer AG, Germany to acquire international rights to the active ingredients Iprovalicarb and Triadimenol. With this acquisition, Dhanuka plans to expand its footprint in more than 20 countries, including the regions of LATAM, EMEA and Asia including India.
- The Results can also be viewed at our website [www.dhanuka.com](http://www.dhanuka.com) and on the website of BSE & NSE where the Company's shares are listed i.e. at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively. Any query from investors can be sent on email at [investors@dhanuka.com](mailto:investors@dhanuka.com).



For and on behalf of  
Dhanuka Agritech Limited

(M.K. Dhanuka)  
Chairman  
DIN : 00628039

Place : Gurugram (Haryana)  
Dated : February 03, 2025



- A. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC. - **Not Applicable**
- B. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES - **Not Applicable**
- C. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) - **Not Applicable**
- D. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - **Not Applicable**